Abstract:BACKGROUND To investigate the prognostic impact of epidermal growth factor receptor ( EGFR ) mutation in clinical stage I lung adenocarcinoma patients. METHODS A total of 952 patients who received surgery and underwent detection of oncogenic driver mutations were retrospectively collected. Recurrence-free survival (RFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared using Log-rank test. Adjusted hazard ratio with 95% confidence interval (aHR, 95%CI) of prognosticator was calculated by Cox proportional-hazards model, and cumulative incidence function was measured by competing risk regression model. RESULTS EGFR mutation was detected in 581(61.0%) patients, and was more frequent in females (63.9%), non-smokers (85.5%), and ground-glass nodule (GGN) (56.6%). EGFR mutation was not associated with recurrence and death in either the entire cohort or GGN cohort. However, for patients with radiologic pure-solid appearance, EGFR mutation was an independent risk factor for RFS (aHR, 1.623, 95%CI, 1.192-2.210) and distant-recurrence (aHR, 1.863, 95%CI, 1.311-2.650), but not OS. Subsequently, subgroup analysis based on EGFR mutation subtypes including 19-Del, L858R, and Rare-mutations in patients with radiologic pure-solid appearance, revealed that all three subtypes were have poorer RFS (19-Del: aHR, 1.424, 95%CI, 0.991-2.047; L858R: aHR, 1.708, 95%CI, 1.172-2.490; Rare-mutations: aHR, 2.500, 95%CI, 1.400-4.465) and higher prevalent distant-recurrence (19-Del: aHR, 1.595, 95%CI, 1.061-2.400; L858R: aHR, 2.073, 95%CI, 1.371-3.140; Rare-mutations: aHR, 2.657, 95%CI, 1.397-5.050) compared with wild-type. CONCLUSIONS In clinical stage I lung adenocarcinoma, EGFR mutation was associated with worse RFS and higher prevalent distant-recurrence in patients with radiologic pure-solid appearance, but not in patients with GGN.

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma